Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
BioCryst Pharmaceuticals, Inc. BCRX
$8.27
-$0.09 (-1.07%)
На 18:00, 12 мая 2023
+129.75%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1588825543.00000000
-
week52high
15.43
-
week52low
7.20
-
Revenue
270827000
-
P/E TTM
-6
-
Beta
2.00865000
-
EPS
-1.31000000
-
Last Dividend
0.00000000
-
Next Earnings Date
03 мая 2023 г. в 11:00
Описание компании
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Oppenheimer | Perform | Outperform | 08 авг 2022 г. |
| Oppenheimer | Perform | Outperform | 05 авг 2022 г. |
| Evercore ISI Group | In-Line | Outperform | 05 авг 2022 г. |
| Barclays | Equal-Weight | Equal-Weight | 05 авг 2022 г. |
| Barclays | Equal-Weight | Overweight | 18 апр 2022 г. |
| RBC Capital | Sector Perform | Sector Perform | 02 ноя 2022 г. |
| Evercore ISI Group | Outperform | In-Line | 02 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Stonehouse Jon P | D | 0 | 100000 | 01 февр 2023 г. |
| Stonehouse Jon P | D | 1008739 | 100000 | 01 февр 2023 г. |
| Stonehouse Jon P | A | 1108739 | 100000 | 01 февр 2023 г. |
| LEE KENNETH B JR | D | 0 | 15000 | 31 янв 2023 г. |
| LEE KENNETH B JR | A | 52118 | 15000 | 31 янв 2023 г. |
| Stonehouse Jon P | A | 10000 | 5000 | 29 дек 2022 г. |
| Stonehouse Jon P | D | 1008739 | 10000 | 29 дек 2022 г. |
| Barnes Alane P | A | 158500 | 158500 | 19 дек 2022 г. |
| Barnes Alane P | A | 232770 | 34000 | 19 дек 2022 г. |
| Thackray Helen M. | A | 238000 | 238000 | 19 дек 2022 г. |
Новостная лента
Why BioCryst Pharmaceuticals Stock Is Soaring Today
The Motley Fool
03 мая 2023 г. в 13:44
BioCryst Pharmaceuticals reported first-quarter earnings Wednesday morning. The financial report painted an overall encouraging picture regarding its main growth driver, Orladeyo.
BioCryst to Report First Quarter 2023 Financial Results on May 3
GlobeNewsWire
19 апр 2023 г. в 07:00
RESEARCH TRIANGLE PARK, N.C., April 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2023 financial results on Wednesday, May 3, 2023.
BioCryst to Present at Upcoming Investor Conferences
GlobeNewsWire
12 апр 2023 г. в 07:00
RESEARCH TRIANGLE PARK, N.C., April 12, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following investor conferences:
BioCryst: Good Candidate For Buyout, But Not For Anything Else
Seeking Alpha
08 мар 2023 г. в 14:01
BioCryst Pharmaceuticals, Inc. has one blockbuster potential marketed drug, but not much of a pipeline. Last year, they shelved two separate programs for different reasons.
Why Shares of BioCryst Pharmaceuticals Jumped Today
The Motley Fool
22 февр 2023 г. в 15:29
A day after the stock plummeted, it bounced back.